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Abstract
Background: Plasma DNA obtained from a pregnant woman contains a mixture of maternal and fetal DNA. The fetal DNA
proportion in maternal plasma is relatively consistent as determined using polymorphic genetic markers across different
chromosomes in euploid pregnancies. For aneuploid pregnancies, the observed fetal DNA proportion measured using
polymorphic genetic markers for the aneuploid chromosome would be perturbed. In this study, we investigated the
feasibility of analyzing single nucleotide polymorphisms using targeted massively parallel sequencing to detect such
perturbations in mothers carrying trisomy 21 fetuses.
Methodology/Principal Findings: DNA was extracted from plasma samples collected from fourteen pregnant women
carrying singleton fetuses. Hybridization-based targeted sequencing was used to enrich 2 906 single nucleotide
polymorphism loci on chr7, chr13, chr18 and chr21. Plasma DNA libraries with and without target enrichment were analyzed
by massively parallel sequencing. Genomic DNA samples of both the mother and fetus for each case were genotyped by
single nucleotide polymorphism microarray analysis. For the targeted regions, the mean sequencing depth of the enriched
samples was 225-fold higher than that of the non-enriched samples. From the targeted sequencing data, the ratio between
fetus-specific and shared alleles increased by approximately 2-fold on chr21 in the paternally-derived trisomy 21 case. In
comparison, the ratio is decreased by approximately 11% on chr21 in the maternally-derived trisomy 21 cases but with
much overlap with the ratio of the euploid cases. Computer simulation revealed the relationship between the fetal DNA
proportion, the number of informative alleles and the depth of sequencing.
Conclusions/Significance: Targeted massively parallel sequencing of single nucleotide polymorphism loci in maternal
plasma DNA is a potential approach for trisomy 21 detection. However, the method appears to be less robust than
approaches using non-polymorphism-based counting of sequence tags in plasma.
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Introduction
Prenatal screening and diagnosis of fetal aneuploidies, such as
trisomy 21 (T21), is an established part of modern obstetrics care.
Conventional prenatal screening is built on parameters such as
maternal age, sonographic and biochemical markers [1]. Since
these parameters are mainly based on phenotypic features, which
are essentially epiphenomena associated with the core molecular
pathology, their diagnostic performance is usually suboptimal.
Pregnancies stratified as high risk by the above screening
approaches require further investigation of fetal genetic materials
obtained via invasive procedures, such as chorionic villus sampling
(CVS) and amniocentesis. These latter procedures carry small, but
definite, risk of miscarriage [2]. The demonstration of fetal DNA
in maternal plasma in 1997 has opened up possibilities for
noninvasive prenatal diagnosis (NIPD) [3].
Maternal plasma DNA contains a mixture of fragmented
maternal and fetal genomic DNA [4]. The large background of
maternal DNA represents a challenge for the interrogation of fetal
chromosomal status. Early studies for NIPD of T21 were
polymorphism-based, requiring the measurements of allelic ratios
and comparing them with the expected normal values [5–7].
These early methods were based on fetal-specific molecular
signatures such as DNA methylation markers [5] and RNA
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fetal DNA concentration to a sufficiently high level such as using
formaldehyde treatment of maternal plasma [7]. However, for the
last approach, there are controversies on the effectiveness of
formaldehyde treatment because this method could not be
replicated consistently by different groups [8–10]. Therefore, the
clinical applicability of such a method remains unclear.
An alternative approach for NIPD of T21 is to measure the
proportion of chromosome 21 (chr21)-derived DNA molecules in a
maternal plasma sample. If a mother is carrying a T21 fetus, the
additional copy of chr21 from the fetus would contribute an
additional amount of chr21 DNA molecules to the maternal
plasma sample, leading to an increased proportion of chr21
sequences [11]. The advent of massively parallel sequencing (MPS)
enhances the precision of DNA quantification to an unprecedent-
ed level, and has enabled the detection of aberrant quantities of
fetal DNA derived from an aneuploid chromosome using a tag-
counting approach [11–14]. Therefore, it is an opportune time to
reinvestigate the feasibility of the allelic ratio approach for the
NIPD of T21 by using MPS. Since single nucleotide polymor-
phisms (SNPs) only account for approximately 1.6% of the human
genome according to the dbSNP Build 135 for human (http://
www.ncbi.nlm.nih.gov/projects/SNP/), conventional non-target-
ed MPS would only include SNP alleles in a small proportion of
sequence reads. In our previous publication, by using a
hybridization-based targeted MPS platform, we demonstrated
the enrichment of DNA molecules within the targeted regions, as
well as the preservation of the allelic ratios of the targeted SNPs in
maternal plasma after target enrichment [15]. Therefore, in this
study, we investigated the feasibility of the allelic ratio approach by
using targeted MPS to preferentially sequence selected SNP loci in
maternal plasma DNA for fetal T21 detection.
Materials and Methods
Ethics statement
Approvals were obtained from the institutional review board of
the Joint Chinese University of Hong Kong - New Territories East
Cluster Clinical Research Ethics Committee. All participants gave
informed written consent.
Subjects and sample collection
We recruited fourteen pregnant women with singleton fetuses
(gestational age ranging from 12 weeks to 13 weeks and 5 days)
from the Department of Obstetrics and Gynaecology, Prince of
Wales Hospital, Hong Kong. Maternal peripheral blood samples
were collected prior to CVS. Following CVS, fetal genomic DNA
samples were obtained from the chorionic villi. The aneuploidy or
euploidy status were confirmed by full karyotyping. Among the
fourteen cases, seven were T21 fetuses and the rest were euploid.
DNA extraction
Maternal peripheral blood samples (5–10 mL) were centrifuged
at 1 600 g for 10 min at 4uC. The plasma portion (2–5 mL) was
recentrifuged at 16 000 g for 10 min at 4uC. We removed any
residual plasma from the blood cell portion by recentrifugation at
2 500 g for 5 min [16]. Plasma DNA was extracted with the DSP
DNA Blood Mini Kit (Qiagen), as described previously [11]. Fetal
and maternal genomic DNA was extracted from chorionic villi
and peripheral blood cells, respectively, with the QIAamp DNA
Blood Mini Kit (Qiagen) according to the manufacturer’s protocol.
The extracted plasma DNA was quantified by real-time PCR
using an ABI 7300 Sequence Detector (Applied Biosystems). A b-
globin real-time PCR assay was performed as described previously
[4]. A conversion factor of 6.6 pg of DNA per cell was used to
calculate the amount of the extracted plasma DNA.
Targeted MPS of plasma DNA libraries
As the plasma DNA molecules were already fragmented in
nature, no additional fragmentation step was required. 10–30 ng
plasma DNA for each case was used for DNA library construction
by the Genomic DNA Sample Preparation Kit (Illumina) as
previously described [15], except for the replacement of the
adaptors and primers with the oligonucleotides from the Multi-
plexing Sample Preparation Oligonucleotide Kit (Illumina) and
the SureSelect Target Enrichment System Kit (Agilent) according
to the manufacturer’s instructions. In order to obtain high fold
sequencing coverage for SNPs, the SureSelect Target Enrichment
System (Agilent) was applied for capturing SNPs in the targeted
regions. As a proof-of-principle study, approximately 5% of the
probes were designed to target a total of 2 906 SNP loci on chr7
(313 SNPs), chr13 (564 SNPs), chr18 (592 SNPs) and chr21 (1 437
SNPs), while the remaining probes were designed for another
project. The above 2 906 SNPs represented a subset of the SNPs in
the Genome-Wide Human SNP Array 6.0 (Affymetrix) (Table S2).
500 ng of each constructed plasma DNA library was incubated
with the probes for 24 h at 65uC. After hybridization, the captured
DNA molecules were eluted and amplified by a 12-cycle PCR
according to manufacturer’s instructions. Libraries with and
without target enrichment were indexed for multiplex sequencing
on a Genome Analyzer IIx (Illumina) in 50-bp62 paired-end
format. An additional 7 cycles of sequencing were performed to
decode the index sequence. All sequenced reads were aligned to
the unmasked human reference genome (Hg18) (http://genome.
ucsc.edu) with the aid of SOAPaligner/soap2 (http://soap.
genomics.org.cn). Two mismatches were allowed during align-
ment. The range of fragment sizes of paired-end reads was defined
as 50–600 bp. Duplicated paired-end reads (e.g., reads with
identical sequences and start–end coordinates) were considered
clones of the same original plasma DNA template. All but one of
the duplicated reads were filtered, leaving only 1 copy for
subsequent bioinformatics analysis as previously described [15].
The allele counting in plasma DNA was based on the SNP loci
contained in the microarray. Since we already knew the position
for each SNP locus, we directly counted the alleles in plasma DNA
according to the maternal and fetal genotyping information which
served as the gold standard. For example, if maternal genotype
was AA and fetal genotype was AB for one SNP, we counted the
copy number of A and B alleles for this SNP locus in plasma DNA
for subsequent analysis.
F-S ratio calculation
We define a SNP as informative if it is homozygous in the
mother (e.g., genotype AA) and heterozygous in the fetus (e.g.,
genotype AB). In this scenario, the B allele is the fetus-specific
allele and the A allele is the allele shared by the mother and fetus.
Informative SNPs were identified according to maternal and fetal
genotyping information. The fetus-specific allelic counts and
shared allelic counts for the informative SNPs were obtained
from the plasma DNA sequencing data, and were used to calculate
the ratio between the fetus-specific alleles and the shared alleles
(expressed as F-S ratio) for chr21 (expressed as FSR21) and the
reference chromosomes (expressed as FSRRef). In this study,
reference chromosomes included all autosomes except chr21 in the
non-targeted sequencing data analysis, and included chr7, chr13
and chr18 in the targeted sequencing data analysis. If a mother is
carrying a euploid fetus, the ratio between FSR21 and FSRRef
(expressed as FSR21
Ref) should be equal to 1 (Figure 1). If a mother
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(referred in this manuscript as paternally-derived T21), the fetal
genotype on chr21 would become ABB. The additional copy of
the fetus-specific allele would increase the FSR21
Ref to 2 (Figure 1).
If the extra copy of chr21 is from the mother (referred in this
manuscript as maternally-derived T21), the fetal genotype on
chr21 would become AAB. The additional copy of the shared
allele would reduce the FSR21
Ref to less than 1 (Figure 1).
Microarray genotyping
Maternal and fetal genomic DNA samples were genotyped with
the Genome-Wide Human SNP Array 6.0 (Affymetrix). The
parental origin of the additional copy of chr21 in seven T21 fetuses
was determined using microarray analysis of the chorionic villus
samples in which the allelic signal intensities for SNPs on chr21
were analyzed. If the fetus has paternally-derived T21, the signal
intensity of the fetus-specific allele (B allele) should be 2-fold higher
than the shared allele (A allele), because the fetal genotype would
become ABB on chr21, and vice versa. Using this approach, one
fetus was identified as a paternally-derived T21, while six were
maternally-derived T21.
Computer simulation
Computer simulation was employed to investigate the accuracy
of the F-S ratio analysis for T21 detection. The statistical model is
based on the assumption that the numbers of fetus-specific and
shared allelic counts should follow a binomial distribution,
according to the fractional fetal DNA concentration in both the
paternally- and maternally-derived T21 models. For example,
assuming the fractional fetal DNA concentration in the reference
chromosomes (chrRef) is f, the probability of detecting the fetus-
specific allele for an informative SNP would be f/2 on chrRef
irrespective of the aneuploidy status of the fetus. On the other
hand, the probability of detecting the fetus-specific allele on chr21
would be f/2 if the mother is carrying a euploid fetus, 2f/(2+f) if
the mother is carrying a paternally-derived T21 fetus, and f/(2+f) if
the mother is carrying a maternally-derived T21 fetus (Figure 1).
For illustration purposes, we assumed equal amounts of informa-
tive allelic counts (the summation of fetus-specific and shared
allelic counts) were obtained from chr21 and chrRef. Based on the
above assumptions, 1 000 euploid and 1 000 T21 cases were
simulated each time for different fractional fetal DNA concentra-
tions to investigate the detection accuracy in both the paternally-
and maternally-derived T21 models.
Results
Efficiency of target enrichment
We defined sequencing depth as the mean number of times
each base had been sequenced in a particular region. On average,
3.1 million and 2.9 million paired-end reads in non-enriched and
enriched samples, respectively, were mapped uniquely to the
reference human genome (Hg18). After filtration of the duplicated
paired-end reads, we calculated the sequencing depth of the
targeted region by dividing the total number of sequenced bases
within the targeted region by the length of the targeted region.
The mean sequencing depth was 0.12 time for the non-enriched
samples and 27 times for the enriched samples, indicating a mean
enrichment of 225-fold (Table S1). This finding was consistent
with our previous publication [15].
Estimation of fractional fetal DNA concentrations
We calculated the fractional fetal DNA concentrations (also
referred to as the fetal DNA proportion) in the non-enriched
samples by using the informative SNPs from all autosomes except
for chr21, according to the equation: fractional fetal DNA
concentration=fetus-specific allelic counts 62/(fetus-specific alle-
lic counts + shared allelic counts) 6100%. The median fractional
fetal DNA concentration for the fourteen cases analyzed in this
study was 15.5% (range: 9.1%–19.7%).
F-S ratio calculation using non-targeted sequencing data
Based on maternal and fetal genotyping information, informa-
tive SNPs were identified on chr21 (range amongst the samples: 1
044 to 1 775 SNPs), and chrRef which included all autosomes
except chr21 (range amongst the samples: 99 581 to 106 950
SNPs). Within the above informative SNPs, fetus-specific allelic
counts (expressed as FC) and shared allelic counts (expressed as
SC) were determined for chr21 (FC21=2 to 19, SC21=87 to 213)
and chrRef (FCRef=390 to 1 622, SCRef=6 880 to 18 892). We
then calculated the FSR21, FSRRef and FSR21
Ref (Table S1). As
shown in Figure 2A, the paternally-derived T21 case
Figure 1. Schematic of T21 detection by F-S ratio calculation. Assuming the fractional fetal DNA concentration in chrRef is f, the F-S ratio
would be f/(2-f) on chrRef irrespective of the aneuploidy status of the fetus. On the other hand, the F-S ratio on chr21 would be f/(2-f) if the mother is
carrying a euploid fetus, 2f/(2-f) if the mother is carrying a paternally-derived T21 fetus, and f/2 if the mother is carrying a maternally-derived T21
fetus. Therefore, the FSR21
Ref would be 1 if the mother is carrying a euploid fetus, would become 2 if the mother is carrying a paternally-derived T21
fetus, and would become (1-f/2) if the mother is carrying a maternally-derived T21 fetus.
doi:10.1371/journal.pone.0038154.g001
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Ref =2.35) could be differentiated from the euploid group
(FSR21
Ref mean 0.91, median 0.96, range: 0.70 to 1.10). On the
other hand, the maternally-derived T21 cases (FSR21
Ref mean 1.10,
median 1.30, range: 0.33 to 1.57) overlapped with the euploid
cases (Mann-Whitney rank sum test, p=0.366).
F-S ratio calculation using targeted sequencing data
Among the 1 437 targeted SNP loci on chr21 and 1 469 SNP
loci on chrRef (including chr7, chr13 and chr18), informative
SNPs (chr21=151 to 273 SNPs, chrRef=145 to 182 SNPs) were
identified for each case. The number of sequenced reads with the
fetus-specific and shared alleles were determined for chr21
(FC21=197 to 761, SC21=3 610 to 7 740) and chrRef
(FCRef=154 to 473, SCRef=2 786 to 5 557) (Table S1). As
shown in Figure 2B, the paternally-derived T21 case
(FSR21
Ref =1.68) could be differentiated from the euploid group
(FSR21
Ref mean 1.06, median 1.06, range: 0.95 to 1.29). Although
the maternally-derived T21 group appeared to have lower FSR21
Ref
values (FSR21
Ref mean 0.94, median 0.93, range: 0.78 to 1.17)
(Mann-Whitney rank sum test, p=0.051), there was still significant
overlapping with the euploid group.
Computer simulation
We used computer simulation to determine the parameters that
would further improve the accuracy of the allelic ratio approach
for T21 detection. First, we fixed the fractional fetal DNA
concentration at 15% and gradually increased the numbers of
informative allelic counts on chr21 and chrRef to investigate the
detection accuracy for fetal T21. Additional informative allelic
counts would improve the detection accuracy in both the
paternally- and maternally-derived T21 models. In order to
obtain accurate detection (sensitivity .99%, specificity .99%),
more informative allelic counts were required for the maternally-
derived T21 detection (informative allelic counts=130 000) than
the paternally-derived T21 detection (informative allelic counts=1
100) (Figure 3A). If the fractional fetal DNA concentration was
reduced to 5%, the corresponding informative allelic counts would
need to be increased to 3 600 000 for detecting maternally-derived
T21 and 3 500 for detecting paternally-derived T21 (Figure 3B).
When the fractional fetal DNA concentration in maternal plasma
was gradually decreased from 40% to 1%, the minimal number of
informative allelic counts would need to be increased in both the
paternally- and maternally-derived T21 scenarios, in order to
maintain a high detection rate (sensitivity .99%, specificity
.99%). The required increase was higher for the maternally-
derived T21 scenario than that for the paternally-derived one
(Figure 4). The sensitivity and specificity chosen for this analysis
were chosen to mirror the recently reported performance of the
non-polymorphic tag counting approach [12–14].
Discussion
In this study, we investigated if the analysis of chromosome-
specific allelic ratio would be useful for the NIPD of fetal
chromosomal aneuploidy. The paternally-derived T21 case was
successfully detected in both non-targeted and targeted sequencing
data. For the maternally-derived T21 cases, this approach became
less effective. Although the mean FSR21
Ref values was lower in the
maternally-derived T21 cases, there was significant overlapping in
the FSR21
Ref values between the euploid and the maternally-
derived T21 cases. The difference in performances between
paternally- and maternally-derived T21 detection was mainly due
to the magnitude of the change in FSR21
Ref, which was increased by
2-fold for paternally-derived T21 and decreased by f/2-fold for
maternally-derived T21 (Figure 1). Since fetal DNA represents a
minor population in maternal plasma, the lower fractional
concentration of fetal DNA would diminish the degree of
FSR21
Ref change in maternally-derived T21. For example, assum-
ing the fractional fetal DNA concentration is 5%, the FSR21
Ref of
maternally-derived T21 would become 0.975, which is very close
to that of a euploid case (FSR21
Ref =1).
Since maternally-derived T21 accounts for the majority of T21
cases in clinical practice, it is necessary to investigate how one
could improve its detection accuracy using the allelic ratio method
[1,17]. One approach is to increase the fractional concentration of
fetal DNA, which would enlarge the magnitude of FSR21
Ref change
in maternally-derived T21. Although an early study attempted to
enrich the fetal DNA proportion by formaldehyde treatment of
maternal plasma [7], this method is not ready for use because it
has not been consistently reproduced by different groups [8–10].
Alternatively, the accuracy of detecting maternally-derived T21
can be improved by increasing the number of informative allelic
counts. According to our simulation analysis, additional informa-
tive allelic counts would, to some extent, compensate for the loss of
detection accuracy caused by the decrease in fractional fetal DNA
concentration (Figure 4). Two approaches can be used to increase
the number of informative allelic counts, namely, recruiting more
informative SNPs and sequencing each locus deeper.
The number of informative SNPs is determined by two factors:
the total number of SNPs on the chromosome of interest for
detection and the frequency of informative SNPs. The latter is the
percentage of detectable informative SNPs amongst a group of
analyzed SNPs. As a proof-of-principle study, we directly used the
fetal genotype information, as determined by microarray-based
analysis of chorionic villus DNA, to maximize the frequency of
informative SNPs. Amongst the fourteen cases recruited for this
study, the mean proportions of SNPs that were informative were
11.9% (range: 11.3% to 12.1%) in all autosomes and 12.9%
(range: 11.0% to 15.0%) in targeted SNP loci. However, the fetal
genomic material would not be available beforehand for actual
NIPD. Therefore, informative SNPs would need to be deduced
Figure 2. T21 detection by F-S ratio in non-targeted and
targeted sequencing data. FSR21
Ref values were calculated to
differentiate the paternally- and maternally-derived T21 from the
euploid fetuses in non-targeted (A) and targeted (B) sequencing data.
(Ma-T21: maternally-derived T21. Pa-T21: paternally-derived T21.).
doi:10.1371/journal.pone.0038154.g002
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both homozygous but with different alleles (e.g., mother is AA and
father is BB). In this scenario, the frequency of informative SNPs
would decrease, because such an approach would exclude any
SNPs in which the father is heterozygous.
In terms of targeted analysis of SNPs, we demonstrated in this
study the feasibility of the hybridization-based enrichment system.
In this proof-of-principle study, we only employed a relatively
small number of probes to capture 2 906 SNP loci on the target
chromosomes. However, it is possible to increase the number of
analyzed SNP loci. For example, if we design probes to cover all
chr21 SNP loci (12 930 SNPs) on the Genome-Wide Human SNP
Array 6.0 (Affymetrix), we could increase the number of
informative SNPs on chr21 to approximately 1 500 SNPs for
each case in the current dataset. If we obtain the same number of
informative SNPs on chrRef and sequence the plasma DNA to a
depth of 87 times, we would harvest approximately 130 000
informative allelic counts (1 500687) on chr21 and chrRef,
respectively. Such numbers would allow the relatively robust
classification of maternally-inherited T21 from the euploid cases,
assuming a fractional fetal DNA concentration of 15% or above
(Figure 3A). Given that in this study the mean frequency of
informative SNPs is approximately 12% and approximately 50%
reads could be mapped back to the targeted regions (with the
Figure 3. Computer simulation for T21 detection for fractional fetal DNA concentrations of 5% and 15%. In order to obtain a specificity
of greater than 99%, the cutoffs for T21 differentiation were chosen at 3 standard deviations above and below the mean F-S ratio of the euploid
group. The sensitivity for paternally- and maternally-derived T21 detection was investigated on different numbers of informative allelic counts on
chr21 and chrRef, respectively, for a fractional fetal DNA concentration of 15% (A). Similar analysis was performed for a fractional fetal DNA
concentration of 5% (B). (Ma-T21: maternally-derived T21. Pa-T21: paternally-derived T21. Sen=sensitivity. Fe%=fractional fetal DNA concentration.
Info AC=informative allelic counts on each of chr21 and chrRef. Info SNP=informative SNPs on each of chr21 and chrRef. Seq depth=sequencing
depth. Info AC=Info SNP6Seq depth).
doi:10.1371/journal.pone.0038154.g003
Diagnosis of Fetal Trisomy 21 by Allelic Ratio
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e38154remaining reads being off-target), the total number of reads
required to obtain 130 000 informative allelic counts would be
approximately 4.3 million (130 000 reads62/(12%650%)), which
was comparable to that of the tag counting approach [12–14].
However, if the fractional fetal DNA concentration is reduced to
5%, the number of reads would need to be increased to
approximately 120 million (Figure 3B), which was more than that
needed for the non-polymorphic tag counting approach [12–14].
5% and 15% were analyzed here because 5% is close to the lower
limit for the non-polymorphism-based tag counting approach at
the depth of sequencing used in a number of recent studies, and
15% is the approximate mean fractional fetal DNA concentration
in the published clinical trials based on the tag counting approach
[12–14].
In order to obtain a sufficient number of allelic counts, an
alternative approach is to sequence more deeply each locus with a
relatively small number of informative SNPs. According to our
previous publication, we demonstrated that each milliliter of
plasma contained approximately 1 000 genome-equivalents of
DNA, which would give rise to 2 000 allelic counts for each locus
[4]. If we could count all of the alleles for each locus in 5 mL
plasma, we would obtain 10 000 allelic counts for each locus. In
this scenario, 26 informative SNPs (13 SNPs on chr21, 13 SNPs on
chrRef) could provide sufficient informative allelic counts for
maternally-derived T21 detection in a sample containing 15%
fetal DNA, representing 130 000 informative allelic counts (10
000613) on chr21 and chrRef, respectively. The number of
informative SNPs would need to be increased to 720 (360 SNPs on
chr21, 360 SNPs on chrRef) for a sample containing a fractional
fetal DNA concentration of 5%. Due to the high read depth
required by this strategy (i.e. 10 000 counts per informative allele),
PCR-based approaches for target enrichment might be alternative
methods for this type of application [18,19].
The targeted massively parallel sequencing of SNP loci in
plasma DNA is thus a feasible method for the NIPD of fetal
aneuploidies. However, when compared with published work
based on tag counting of nonpolymoprhic loci for T21 detection
[12–14], this approach appears to be less effective and robust
because it requires the parental genotyping information and needs
more sequencing reads if the fractional fetal DNA concentration is
low as illustrated in this proof-of-principle study. In addition, the
costs and time required for target enrichment would need to be
taken into account. Nevertheless, this study has also outlined the
strategies that one could use to further improve this approach.
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